CONMED Q4 Net Sales Up 10.1% to $340.4M; FY Sales $1.24B
Ticker: CNMD · Form: 8-K · Filed: Jan 31, 2024 · CIK: 816956
Complexity: simple
Sentiment: bullish
Topics: earnings, financial-results, sales-growth
TL;DR
**CONMED just dropped strong Q4 and full-year sales numbers, signaling healthy growth.**
AI Summary
CONMED Corporation filed an 8-K on January 31, 2024, to announce its financial results for the fourth quarter and full year ended December 31, 2023. The company reported net sales of $340.4 million for Q4 2023, an increase of 10.1% year-over-year, and full-year net sales of $1.24 billion, up 8.3%. This matters to investors because strong sales growth indicates healthy demand for CONMED's medical devices, which could lead to increased profitability and a higher stock valuation.
Why It Matters
This filing provides crucial insight into CONMED's recent financial performance, directly impacting investor confidence and future stock price expectations. Strong sales figures suggest the company is effectively growing its market share and revenue.
Risk Assessment
Risk Level: low — This 8-K filing primarily reports positive financial results, which generally reduces perceived risk for investors.
Analyst Insight
A smart investor would review CONMED's detailed earnings report for further insights into profitability and guidance, considering these strong sales figures as a positive indicator for the company's operational health and potential for continued growth.
Key Numbers
- $340.4 million — Q4 2023 Net Sales (Represents a 10.1% increase year-over-year, indicating strong quarterly growth.)
- $1.24 billion — Full Year 2023 Net Sales (Represents an 8.3% increase year-over-year, showing consistent annual growth.)
- 10.1% — Q4 2023 Sales Growth (The percentage increase in net sales for the fourth quarter compared to the prior year.)
- 8.3% — Full Year 2023 Sales Growth (The percentage increase in net sales for the full year compared to the prior year.)
Key Players & Entities
- CONMED Corporation (company) — the registrant filing the 8-K
- $340.4 million (dollar_amount) — net sales for Q4 2023
- 10.1% (dollar_amount) — year-over-year increase in Q4 2023 net sales
- $1.24 billion (dollar_amount) — net sales for the full year 2023
- 8.3% (dollar_amount) — year-over-year increase in full-year 2023 net sales
- January 31, 2024 (date) — date of earliest event reported and filing date
- December 31, 2023 (date) — end of the reporting period for Q4 and full year
Forward-Looking Statements
- CONMED's stock price will see a positive reaction due to strong sales growth. (CNMD) — medium confidence, target: 2024-02-07
- Analysts will revise their revenue forecasts for CONMED upwards for 2024. (CNMD) — medium confidence, target: 2024-03-31
FAQ
What was CONMED Corporation's net sales for the fourth quarter of 2023?
CONMED Corporation reported net sales of $340.4 million for the fourth quarter ended December 31, 2023, as stated in the filing.
By what percentage did CONMED's net sales increase in Q4 2023 compared to the previous year?
The filing indicates that CONMED's net sales for Q4 2023 increased by 10.1% compared to the prior year's fourth quarter.
What were CONMED's total net sales for the full fiscal year 2023?
For the full fiscal year ended December 31, 2023, CONMED Corporation achieved total net sales of $1.24 billion.
What was the year-over-year growth rate for CONMED's full fiscal year 2023 net sales?
CONMED's full fiscal year 2023 net sales grew by 8.3% compared to the previous fiscal year, according to the filing.
What was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing was January 31, 2024.
Filing Stats: 496 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-01-31 16:14:18
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value CNMD NYSE Indicate by che
Filing Documents
- form8k-31428_cnmd.htm (8-K) — 25KB
- ex99-1.htm (EX-99.1) — 361KB
- image_001.jpg (GRAPHIC) — 4KB
- 0001174947-24-000144.txt ( ) — 582KB
- cnmd-20240131.xsd (EX-101.SCH) — 3KB
- cnmd-20240131_lab.xml (EX-101.LAB) — 33KB
- cnmd-20240131_pre.xml (EX-101.PRE) — 22KB
- form8k-31428_cnmd_htm.xml (XML) — 3KB
02
Item 2.02 Results of Operations and Financial Condition. On January 31, 2024, CONMED Corporation issued a press release announcing financial results for the fourth quarter ended December 31, 2023. A copy of this press release is attached hereto as Exhibit 99.1. The information in this Current Report on Form 8-K that is furnished under "Item 2.02. Results of Operations and Financial Condition" and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Act of 1934, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits The following exhibits are included herewith: Exhibit No. Description of Exhibit 99.1 Press Release dated January 31, 2024, issued by CONMED Corporation. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 31, 2024 CONMED CORPORATION (Registrant) By: /s/ Todd W. Garner Name: Todd W. Garner Title: Executive Vice President- Chief Financial Officer